This presentation contains forward‐looking statements that reflect the current views of management, and which are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the Straumann Group to differ materially from those expressed or implied in this presentation. Statements are made on the basis of management's views and assumptions regarding future events and business performance at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditions, pandemics, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside Straumann's control. Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect, actual outcomes may vary materially from those forecasted or expected. Straumann is providing the information in this presentation as of this date and does not undertake any obligation to update any statements contained in it as a result of new information, future events or otherwise. This presentation constitutes neither an offer to sell nor a solicitation to buy any securities.
2
2
AGENDA
Highlights
Guillaume Daniellot
Financials
Marcel Kellerhals
Recent achievements & strategy
Guillaume Daniellot
Outlook 2023
Guillaume Daniellot
Q&A
Guillaume Daniellot, Marcel Kellerhals
3
3
HIGHLIGHTS
Guillaume Daniellot, CEO
4
4
SOLID HALF-YEAR RESULTS LIFTED BY SECOND QUARTER
Revenue in CHF
Organic revenue growth1
Core profitability
1.2 bn
7.5%
26%
621 m revenue in Q2 Dynamic patient flow in all regions
REVENUE DEVELOPMENT BREAKDOWN IN CHF MILLION, ROUNDED
+5.4%
+11.7%
organic
9
23
621
589
11
22
8
556
‐42
Change in organic growth
+8.8%
+7.0%
+23.1%
+20.1%
Revenue
FX effect
M&A effect
Adjusted
EMEA
NAM
APAC
LATAM
Revenue
Q2 2022
revenue base
Q2 2023
10
10
Attachments
Original Link
Original Document
Permalink
Disclaimer
Straumann Holding AG published this content on 15 August 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 August 2023 05:15:02 UTC.
Straumann Holding AG is a Switzerland-based company active in the field of implant and restorative dentistry and oral tissue regeneration. In collaboration with clinics, research institutes and universities, the Group researches and develops implants, instruments, computer-aided design/manufacturing (CAD/CAM) prosthetics and tissue regeneration products for use in tooth replacement and restoration solutions or to prevent tooth loss. Straumann Holding AG also offers a range of services to the dental profession worldwide, including training and education, provided in collaboration with the International Team for Implantology (ITI). Its products and services are available in a number of countries through the Groupâs headquarters and through a network of subsidiaries and technology partners located in Europe, North America, the Asia/Pacific region and in Latin America, including Dental Wings Inc based in Canada and Createch Medical SL based in Spain.
STRAUMANN HOLDING AG 
